Efficacy and safety of eRVR patients treated with telaprevir, peginterferon alfa-2A and ribavirin: SVR Data from the German non-interventional PAN Study

被引：0

作者：

Christensen, Stefan ^{[1
]}

Boeker, Klaus H. ^{[2
]}

Eisenbach, Christoph ^{[3
]}

Schuchmann, Marcus ^{[4
]}

Lutz, Thomas ^{[5
]}

Heyne, Renate ^{[6
]}

Moog, Gero ^{[7
]}

Mauss, Stefan ^{[8
]}

Jung, Maria-Christina ^{[9
]}

Teuber, Gerlinde ^{[10
]}

Emke, Franz ^{[11
]}

Naumann, Uwe ^{[12
]}

Doss, Margareta Frank ^{[13
]}

von Lucadou, Armand ^{[14
]}

Alshuth, Ulrich ^{[15
]}

Hueppe, Dietrich ^{[16
]}

机构：

[1] CIM, Munster, Germany

[2] Ctr Hepatol, Hannover, Germany

[3] Heidelberg Univ, Dept Gastroenterol, Heidelberg, Germany

[4] Johannes Gutenberg Univ Mainz, Dept Med Gastroenterol & Hepatol 1, D-55122 Mainz, Germany

[5] Infektiologikum, Frankfurt, Germany

[6] Liver & Study Ctr Checkpoint, Berlin, Germany

[7] Ctr Gastroenterol, Kassel, Germany

[8] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany

[9] Ctr Liver, Munich, Germany

[10] IFS, Frankfurt, Germany

[11] Ctr Gastroenterol, Osnabruck, Germany

[12] Praxiszentrum Kaiserdamm, Ctr Addict Med Hepatol & HIV, Berlin, Germany

[13] Ctr Gastroenterol, Marburg, Germany

[14] Ctr Internal Med, Nurnberg, Germany

[15] Roche Pharma AG, Virol, Grenzach Wyhlen, Germany

[16] Ctr Gastroenterol, Herne, Germany

来源：

HEPATOLOGY | 2013年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1905

引用

页码：1127A / 1127A

页数：1

共 50 条

[1] REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
Mauss, S.
Boeker, K. H. W.
Eisenbach, C.
Moeller, B.
Moog, G.
Lutz, T.
Naumann, U.
Christensen, S.
Jung, M. -C.
Teuber, G.
Doss, M. Frank
Schuchmann, M.
Schott, E.
Alshuth, U.
Hueppe, D.
[J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S357 - S358
[2] Real-world efficacy and safety of 28 week-therapy containing boceprevir, peginterferon alfa-2a and ribavirin in treatment-naive patients: first SVR data of German non-interventional PAN Study
Buggisch, Peter
Schober, Andreas
Bruch, Harald-Robert
Antoni, Christoph
Loehr, Hanns-Friedrich F.
Herrmann, Andreas
Steffens, Hermann
Moog, Gero
Haessner, Joachim
Hoerster, Hans-Georg
John, Christine
Schlueter, Hans-Joachim
Link, Ralph
Heyne, Renate
Spengler, Ulrich
Alshuth, Ulrich
Boeker, Klaus H.
[J]. HEPATOLOGY, 2013, 58 : 1159A - 1159A
[3] REAL-WORLD EFFICACY AND SAFETY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
Moog, G.
Schober, A.
Antoni, C.
Bruch, H. R.
Herrmann, A.
John, C.
Steffens, H.
Leuschner, M.
Spengler, U.
Moeller, B.
Isernhagen, K.
Hueppe, D.
Alshuth, U.
Mauss, S.
[J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S359 - S360
[4] REAL-WORLD EFFICACY OF BOCEPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN IN TREATMENT-EXPERIENCED PATIENTS: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
Spengler, U.
Schober, A.
John, C.
Bruch, H. R.
Heyne, R.
Antoni, C.
Herrmann, A.
Schott, E.
Steffens, H.
Hoerster, H. -G.
Hueppe, D.
Alshuth, U.
Mauss, S.
Buggisch, P.
[J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S374 - S374
[5] Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients
Lawitz, Eric
Rodriguez-Torres, Maribel
Muir, Andrew J.
Kieffer, Tara L.
McNair, Lindsay
Khunvichai, Ariya
McHutchison, John G.
[J]. JOURNAL OF HEPATOLOGY, 2008, 49 (02) : 163 - 169
[6] Beneficial effect of treatment individualization for patients with chronic hepatitis C receiving peginterferon alfa-2a and ribavirin in a large non-interventional cohort study
Hofmann, Wolf P.
Mauss, Stefan
Zehnter, Elmar
Hueppe, Dietrich
Pfeiffer-Vornkahl, Heike
Alshuth, Ulrich
Schott, Eckart
[J]. HEPATOLOGY, 2014, 60 : 703A - 703A
[7] Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-infected Patients: SVR24 Final Study Results
Sulkowski, Mark S.
Sherman, Kenneth E.
Soriano, Vincent
Rockstroh, Juergen
Dieterich, Douglas T.
Girard, Pierre-Marie
Bsharat, Mohammad
Henshaw, Joshua
Rubin, Raymond A.
Garg, Varun
Adda, Nathalie
[J]. HEPATOLOGY, 2012, 56 : 219A - 219A
[8] IMPROVED SUSTAINED VIROLOGIC RESPONSE (SVR) RATES IN "DIFFICULT-TO-CURE" PATIENTS TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: AN ANALYSIS FROM THE PROVE3 STUDY
Manns, M. P.
Muir, A. J.
Adda, N.
McHutchison, J. G.
Terrault, N.
Bengtsson, L.
George, S.
Di Bisceglie, A. M.
[J]. JOURNAL OF HEPATOLOGY, 2010, 52 : S115 - S115
[9] Sustained viral response (SVR) with Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who were non responders (NR) to Peginterferon alfa-2b and ribavirin
Gitlin, N
Muther, KD
[J]. HEPATOLOGY, 2004, 40 (04) : 343A - 343A
[10] Twice Daily Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Liver Transplant Recipients: Interim Safety/Efficacy of the REFRESH Study
Brown, R.
Russo, M.
Levitsky, J.
Brown, K.
Fontana, R.
Vargas, H.
Yoshida, E.
Bsharat, M.
Rubin, R.
[J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 145 - 145

← 1 2 3 4 5 →